XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2025
Dec. 31, 2024
Current Assets    
Cash and cash equivalents $ 18,169 $ 13,242
Short-term investments 45 447
Accounts receivable (net of allowance for doubtful accounts of $93 in 2025 and $89 in 2024) 12,120 10,278
Inventories (excludes inventories of $5,412 in 2025 and $4,193 in 2024 classified in Other assets - see Note 6) 6,444 6,109
Other current assets 10,779 8,706
Total current assets 47,557 38,782
Investments 1,117 463
Property, Plant and Equipment, at cost, net of accumulated depreciation of $20,605 in 2025 and $19,155 in 2024 25,639 23,779
Goodwill 21,587 21,668
Other Intangibles, Net 15,313 16,370
Other Assets 18,333 16,044
Total Assets 129,546 117,106
Current Liabilities    
Loans payable and current portion of long-term debt 1,405 2,649
Trade accounts payable 4,147 4,079
Accrued and other current liabilities 16,186 15,694
Income taxes payable 4,848 3,914
Dividends payable 2,042 2,084
Total current liabilities 28,628 28,420
Long-Term Debt 39,969 34,462
Deferred Income Taxes 1,381 1,387
Other Noncurrent Liabilities 7,661 6,465
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2025 and 2024 1,788 1,788
Other paid-in capital 44,832 44,704
Retained earnings 72,231 63,069
Accumulated other comprehensive loss (5,202) (4,945)
Stockholders' equity before deduction for treasury stock 113,649 104,616
Less treasury stock, at cost: 1,089,754,712 shares in 2025 and 1,049,466,187 shares in 2024 61,799 58,303
Total Merck & Co., Inc. stockholders’ equity 51,850 46,313
Noncontrolling Interests 57 59
Total equity 51,907 46,372
Liabilities and Equity $ 129,546 $ 117,106